LENZ Therapeutics (NASDAQ:LENZ – Get Free Report) will likely be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter.
LENZ Therapeutics Trading Down 5.8 %
Shares of LENZ opened at $23.49 on Monday. The stock has a fifty day moving average of $26.54 and a two-hundred day moving average of $27.01. LENZ Therapeutics has a fifty-two week low of $14.42 and a fifty-two week high of $38.93.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and issued a $38.00 price target on shares of LENZ Therapeutics in a report on Thursday, November 7th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, LENZ Therapeutics has an average rating of “Buy” and an average target price of $35.40.
LENZ Therapeutics Company Profile
LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Read More
- Five stocks we like better than LENZ Therapeutics
- The 3 Best Retail Stocks to Shop for in August
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- Dividend Capture Strategy: What You Need to Know
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- What is the FTSE 100 index?
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for LENZ Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LENZ Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
